1. Role of adjuvant HER-2 Agents and during of therapy
2. Chemotherapy backbone considerations
3. Pathologic complete response
4. Neoadjuvant systemic therapy and response modified approach
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/
2.von Minckwitz G et al. NEJM. 2017;377(2):122-131. doi:10.1056/NEJMOA1703643/
3.Slamon D et al.. NEJM. 2011;365(14):1273-1283. doi:10.1056/NEJMOA0910383
4.Piccart M et al. JCO. 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204
5.Martin M et al. Lancet Oncol. 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-9
6.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/
7.Gianni L et al. Lancet Oncol. 2014;15(6):640-647. doi:10.1016/S1470-2045(14)70080-4
8.Symmans WF et al.. J Clin Oncol. 2017;35(10):1049-1060. doi:10.1200/JCO.2015.63.1010
9.Gianni L et al. Lancet Oncol. 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7
10.Gianni L et al. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9
11.Gilboa S et al. Eur J Cancer. 2021;153:190-202. doi:10.1016/J.EJCA.2021.04.044
12.Tolaney SM et al. NEJM. 2015;372(2):134-141. doi:10.1056/NEJMOA1406281/
13.Cameron D et al. Lancet. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2
14.Earl HM et al. Lancet. 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-6
15.Pivot X et al. Lancet. 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-1
16.Perez EA et al. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730
17.Romond EH et al. NEJM. 2005;353(16):1673-1684. doi:10.1056/NEJMOA052122/
18.Ennis S et al.. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
19.Hudis CA. NEJM. 2007;357(1):39-51. doi:10.1056/NEJMRA043186
20.Slamon DJ et al. Science. 1987;235(4785):182-191. doi:10.1126/SCIENCE.3798106
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
1. Role of adjuvant HER-2 Agents and during of therapy
2. Chemotherapy backbone considerations
3. Pathologic complete response
4. Neoadjuvant systemic therapy and response modified approach
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/
2.von Minckwitz G et al. NEJM. 2017;377(2):122-131. doi:10.1056/NEJMOA1703643/
3.Slamon D et al.. NEJM. 2011;365(14):1273-1283. doi:10.1056/NEJMOA0910383
4.Piccart M et al. JCO. 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204
5.Martin M et al. Lancet Oncol. 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-9
6.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/
7.Gianni L et al. Lancet Oncol. 2014;15(6):640-647. doi:10.1016/S1470-2045(14)70080-4
8.Symmans WF et al.. J Clin Oncol. 2017;35(10):1049-1060. doi:10.1200/JCO.2015.63.1010
9.Gianni L et al. Lancet Oncol. 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7
10.Gianni L et al. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9
11.Gilboa S et al. Eur J Cancer. 2021;153:190-202. doi:10.1016/J.EJCA.2021.04.044
12.Tolaney SM et al. NEJM. 2015;372(2):134-141. doi:10.1056/NEJMOA1406281/
13.Cameron D et al. Lancet. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2
14.Earl HM et al. Lancet. 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-6
15.Pivot X et al. Lancet. 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-1
16.Perez EA et al. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730
17.Romond EH et al. NEJM. 2005;353(16):1673-1684. doi:10.1056/NEJMOA052122/
18.Ennis S et al.. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
19.Hudis CA. NEJM. 2007;357(1):39-51. doi:10.1056/NEJMRA043186
20.Slamon DJ et al. Science. 1987;235(4785):182-191. doi:10.1126/SCIENCE.3798106
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology